 Presentations to highlight the Companys broad expertise addressing both novel and well-established targets in neurodegenerative diseasesLAUSANNE, Switzerland, July 23, 2020 GLOBE NEWSWIRE -- AC Immune SA NASDAQ: ACIU, a Swiss-based, clinical-stage biopharmaceutical company, with a broad pipeline focused on neurodegenerative diseases, today announced two oral presentations will be delivered at this years Alzheimers Association International Conference AAIC which takes place virtually July 27 31, 2020.Key data will be presented on the Companys alpha-synuclein-positron emission tomography PET tracer program along with a second oral presentation by the Coordinating Principal Investigator of the Phase 1b trial of the anti-Abeta vaccine ACI-24 in Down syndrome, Dr. Michael Rafii who is a world authority on Down syndrome-related Alzheimers disease. Both research programs are the most advanced in their field.Prof. Andrea Pfeifer, CEO of AC Immune SA, commented: This years AAIC presentations reflect the ongoing strength and depth of our industry leading pipeline. There is increasing recognition that the complexity of neurodegenerative disease pathology will only be solved utilizing the type of diversified approach pioneered by AC Immune. This is why our pipeline spans both cutting-edge therapeutic and diagnostic programs on well-established targets like Abeta, as well as novel targets and mechanisms.Compelling results1 just published from the first large, multi-national study to track clinical and biomarker changes of Down syndrome-related Alzheimers disease further validate the approach of testing our anti-Abeta vaccine ACI-24 in individuals with Down syndrome as a key population for trials to target Alzheimers disease in genetic, more homogeneous populations.The presentations further highlight the enduring power of our clinically validated proprietary MorphomerTM and SupraAntigenTM platforms to accelerate the discovery, design and development of novel medicines and diagnostics to target misfolded proteins.Scientific updates at the AAIC 2020 Virtual Event, July 2731, 2020Alpha-synuclein PET tracer Title: Developing a novel alpha-synuclein-positron emission tomography PET tracer for the diagnosis of a-synucleinopathies Date: Tuesday, July 28, 2020 12:00am 11:59pm Session: Neuroimaging: Other Neurodegenerative Disorders Presenter: Oral presentation by Dr. Francesca Capotosti ACI-24 anti-Abeta vaccine Title: ACI-24 Vaccine in Adults with Down Syndrome 3 Star Trial Date: Wednesday, July 29, 2020 12:00 am 11:59pm Session: Human: Putative Therapeutic Results for Alzheimers and Related Dementias Presenter: Oral presentation by Dr. Michael Rafii, Alzheimers Therapeutic Research Institute, Keck School of Medicine of University of Southern California References 1. Fortea et al, Lancet 2020; 395: 198897About AC Immune SA AC Immune SA is a Nasdaq-listed clinical-stage biopharmaceutical company, which aims to become a global leader in precision medicine for neurodegenerative diseases. The Company utilizes two proprietary platforms, SupraAntigenTM and MorphomerTM, to design, discover and develop small molecule and biological therapeutics as well as diagnostic products intended to diagnose, prevent and modify neurodegenerative diseases caused by misfolding proteins. The Companys pipeline features nine therapeutic and three diagnostic product candidates, with six currently in clinical trials. It has collaborations with major pharmaceutical companies including Genentech, a member of the Roche group, Eli Lilly and Company and Janssen Pharmaceuticals.For further information, please contact:Head of Investor Relations Joshua Drumm, Ph.D. AC Immune Phone: 1 917 809 0814 Email: US Media Katie Gallagher LaVoieHealthScience Phone: 1 617 792 3937 Email: Global Head of Communications Judith Moore AC Immune Phone: 41 79 826 63 82 Email: European Investors Media Chris Maggos LifeSci Advisors Phone: 41 79 367 6254 Email: Forward looking statements This press release contains statements that constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or AC Immunes strategies or expectations. In some cases, you can identify these statements by forward-looking words such as may, might, will, should, expects, plans, anticipates, believes, estimates, predicts, projects, potential, outlook or continue, and other comparable terminology. Forward-looking statements are based on managements current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include those described under the captions Item 3. Key Information Risk Factors and Item 5. Operating and Financial Review and Prospects in AC Immunes Annual Report on Form 20-F and other filings with the Securities and Exchange Commission. These include: the impact of Covid-19 on our business, suppliers, patients and employees and any other impact of Covid-19. Forward-looking statements speak only as of the date they are made, and AC Immune does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement. 